Photo generated from meetings.asco.org
Jun 3, 2024, 13:08
Gilberto Lopes: In phase 3 EVOKE-01 study improvement of OS was noted in patients without response to prior IO
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:
“LBA out: Phase 3 EVOKE-01 study. Sacituzumab vs Docetaxel… and… no better! Underwhelming results. One subgroup to note ‘Clinically meaningful improvement of OS was noted in patients without response to prior IO’. 383 patients OS 8.3 vs 11.8 for these patients HR 0.75 (0.58–0.97).”
Read further
Source: Gilberto Lopes/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 2, 2024, 13:02
Dec 2, 2024, 12:44
Dec 2, 2024, 12:39
Dec 2, 2024, 12:36
Dec 2, 2024, 12:32
Dec 2, 2024, 12:31